Alterity Therapeutics
Dr Stamler joined the Company in June 2017 as Chief Medical Officer and Senior Vice President Clinical Development.
Dr Stamler has significant pharmaceutical development and commercialisation experience including three New Drug Application approvals with the US FDA for drugs in the neurological space. His succession aligns with the next phase of Alterity's commercial strategy and comes at a time when the company is preparing to advance its lead compound ATH434 to Phase 2 Clinical trials.
This person is not in any offices
Alterity Therapeutics
1 followers
Alterity is developing first-in-class therapies to treat neurodegenerative disease.